ZIOPHARM ONCOLOGY INC (ZIOP)

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. The company is headquartered in Boston, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2004-08-20. The firm is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The company has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Company Info

ZIOPHARM ONCOLOGY INC

One First Avenue, Parris Building 34, Navy Yard Plaza

Boston MASSACHUSETTS 02129

P: 16172591970.0

CEO: Heidi Hagen

Employees: 103

Website: http://www.ziopharm.com/